Background-Topical glucocorticoids commonly are used in the management of canine atopic dermatitis to control and prevent allergy flares. Compounding commercial veterinary wipe/pad products to include dexamethasone sodium phosphate (Dex SP) can simplify treatment protocols for owners. Dex SP has not been evaluated for stability when added to wipes/pads. Hypothesis/objective -To evaluate the stability of Dex SP when compounded in three commercial veterinary wipe/pad products containing chlorhexidine. Methods and materials -Dex SP

A 2‐year‐old spayed female domestic short haired cat presented for evaluation of chronic lethargy, inappetence and otitis media/interna that developed secondary to an inflammatory polyp, which had been removed via traction a month prior to presentation. Upon presentation, the cat displayed mild vestibular ataxia and left head tilt, in addition to a bulging left tympanic membrane. Therapy with broad‐spectrum antibiotic therapy and anti‐inflammatory corticosteroids was initiated, however the cat soon developed signs of central vestibular disease and obtunded mentation. Magnetic resonance imaging revealed left‐sided otitis media/interna and cerebellar abscessation. Surgical debridement of the abscess was indicated but declined by the owner in favour of euthanasia.

An 8‐year‐old, neutered, male Golden Retriever presented for progressive alopecia and pruritus along the dorsum. Histopathology revealed granulomatous mural folliculitis, which is a rare inflammatory skin condition in dogs. Treatment with Atopica resulted in hair regrowth and good control of pruritus. However, switching to generic modified cyclosporine resulted in relapse of alopecia and pruritus, which resolved within 2 months after returning to the Food and Drug Administration approved veterinary product.